Original Study| Volume 15, ISSUE 6, e1073-e1080, December 2017

Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer



      An important clinical question of great interest to clinicians is how to best sequence androgen receptor targeted agents (ARTAs) and chemotherapy for metastatic castration-resistant prostate cancer (mCRPC), but the answer is still unclear.

      Materials and Methods

      To evaluate and compare the clinical outcomes of ARTA and docetaxel (DTX) as second-line treatment in the post first-line ARTA, we conducted a retrospective analysis of chemotherapy-naive mCRPC patients who had received sequential treatment with ARTA followed by another ARTA (ARTA-ARTA) or ARTA followed by DTX (ARTA-DTX).


      A total of 97 patients were treated with the ARTA-ARTA sequence and 42 with the ARTA-DTX sequence. A prostate-specific antigen (PSA) response to the second-line treatment was observed in 18.6% in the ARTA-ARTA and in 33.3% in the ARTA-DTX sequence, but the difference in PSA response was not statistically significant (P = .057). The median progression-free survival (PFS) was significantly different between ARTA and DTX in the second-line treatment (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.24-0.59; P < .001). The favorable outcome in the ARTA-DTX sequence compared with the ARTA-ARTA sequence remained (HR, 0.51, 95% CI, 0.33-0.80; P = .004) in the combined PFS (first-line PFS + second-line PFS). However, no statistically significant difference in overall survival (OS) between the 2 groups was observed (HR, 0.60; 95% CI, 0.34-1.09; P = .095). In multivariate analysis, the ARTA-DTX sequence was identified as an independent prognostic factor for combined PFS, but not OS.


      ARTA-DTX might improve clinical outcomes in terms of second-line PFS and combined PFS, compared with the ARTA-ARTA sequence. However, this significance was not observed for OS.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Flaig T.W.
        • Potluri R.C.
        • Ng Y.
        • Todd M.B.
        • Mehra M.
        Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data.
        Cancer Med. 2016; 5: 182-191
        • Schweizer M.T.
        • Zhou X.C.
        • Wang H.
        • et al.
        The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
        Eur Urol. 2014; 66: 646-652
        • van Soest R.J.
        • van Royen M.E.
        • de Morree E.S.
        • et al.
        Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
        Eur J Cancer. 2013; 49: 3821-3830
        • Yamada Y.
        • Matsubara N.
        • Tabata K.I.
        • et al.
        Abiraterone acetate after progression with enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.
        BMC Res Notes. 2016; 9: 471
        • Azad A.A.
        • Eigl B.J.
        • Murray R.N.
        • Kollmannsberger C.
        • Chi K.N.
        Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
        Eur Urol. 2015; 67: 23-29
        • Loriot Y.
        • Bianchini D.
        • Ileana E.
        • et al.
        Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).
        Ann Oncol. 2013; 24: 1807-1812
        • Noonan K.L.
        • North S.
        • Bitting R.L.
        • Armstrong A.J.
        • Ellard S.L.
        • Chi K.N.
        Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.
        Ann Oncol. 2013; 24: 1802-1807
        • de Bono J.S.
        • Smith M.R.
        • Saad F.
        • et al.
        Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302.
        Eur Urol. 2017; 71: 656-664
        • Oh W.K.
        • Miao R.
        • Vekeman F.
        • et al.
        Real-world characteristics and outcomes of patients with metastatic castration-resistant prostate cancer receiving chemotherapy versus androgen receptor-targeted therapy after failure of first-line androgen receptor-targeted therapy in the community setting.
        Clin Genitourin Cancer. 2017; ([Epub ahead of print])
        • Ryan C.J.
        • Smith M.R.
        • de Bono J.S.
        • et al.
        Abiraterone in metastatic prostate cancer without previous chemotherapy.
        N Engl J Med. 2013; 368: 138-148
        • Beer T.M.
        • Armstrong A.J.
        • Rathkopf D.E.
        • et al.
        Enzalutamide in metastatic prostate cancer before chemotherapy.
        N Engl J Med. 2014; 371: 424-433
        • Matsubara N.
        • Uemura H.
        • Fukui I.
        • et al.
        Phase-1 study of abiraterone acetate in chemotherapy-naive Japanese patients with castration-resistant prostate cancer.
        Cancer Sci. 2014; 105: 1313-1320
        • Matsubara N.
        • Uemura H.
        • Satoh T.
        • et al.
        A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).
        Jpn J Clin Oncol. 2014; 44: 1216-1226
        • Steensma D.P.
        Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous.
        J Clin Oncol. 2007; 25 (author reply 1148-1149): 1148
        • Scher H.I.
        • Morris M.J.
        • Stadler W.M.
        • et al.
        Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3.
        J Clin Oncol. 2016; 34: 1402-1418
        • Chi K.N.
        • Annala M.
        • Sunderland K.
        • et al.
        A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).
        J Clin Oncol. 2017; 35 (abstract 5002)